Latest News and Press Releases
Want to stay updated on the latest news?
-
NEW HAVEN, Conn., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
-
Vabomere monotherapy was associated with increased clinical cure, decreased mortality, and was well tolerated compared to best available therapy (BAT) -Data used by CMS in decision to grant a new...
-
- Total consideration of up to $265 million (including potential royalties) -- Expands on existing commercial and co-development agreement for Baxdela® (delafloxacin) - NEW HAVEN, Conn. and FLORENCE,...
-
NEW HAVEN, Conn., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
-
Melinta Therapeutics to Give New Presentations on Antibiotics Portfolio and Pipeline at IDWeek™ 2018
NEW HAVEN, Conn., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
-
Recommended to be approved for treatment of: Complicated intra-abdominal (cIAI) and urinary tract infections (cUTI) -Hospital-acquired pneumonia including ventilator associated pneumonia...
-
NEW HAVEN, Conn., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
-
Melinta Therapeutics to Host Meetings at the Morgan Stanley 16th Annual Global Healthcare Conference
NEW HAVEN, Conn., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
-
NEW HAVEN, Conn., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
-
Solid Performance from New Product Launches VabomereTM Granted NTAP Status by CMS Strengthened Financial Position Supports Continued Growth Completed Expansion and Cross-Training of Experienced...